REFERENCES
1.-Tentori F, Blayney MJ, Albert JM, et al. Mortality risk. for
dialysis patients with different levels of serum calcium, phosphorus,
and PTH: the dialysis outcomes and practice patterns study (DOPPS). Am J
Kidney Dis. 2008;52(3):519–530.
2.- Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid
hormone, and cardiovascular disease in haemodialysis patients: the USRDS
waves 1, 3, and 4 study. JASN. 2005;16(6):1788–1793.
3.- Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism,
mortality, and morbidity in maintenance haemodialysis. J Am Soc Nephrol.
2004;15(8):2208–2218.
4.-Kimata N, Albert JM, Akiba T, et al. Association of mineral
metabolism factors with all-cause and cardiovascular mortality in
haemodialysis patients: the Japan dialysis outcomes and practice
patterns study. Hemodial Int. 2007;11(3):340–348.
5.- Ying L, Wen-Chin L, Ben-Chung C, et al. Association between the
achievement of target range CKD-MBD markers and mortality in prevalent
haemodialysis patients in Taiwan by using the kidney disease: improving
global outcomes clinical guidelines. Biomed Res Int. 2016:1523124.
6.- KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis,
Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral
and Bone Disorder (CKD-MBD)Kidney International Supplements. 2017; 7:
1–59.
7.- Pereira L, Magalhaes J, Mendonça L, et al. Evaluation of Renal
Osteodystrophy and Serum Bone-Related Biomarkers in a Peritoneal
Dialysis Population. J Bone Miner Res. 2022; 37(9):1689-1699.
8.- Cozzolino M, Gallieni M, Chiarelli G, et al. Calcium and phosphate
handling in peritoneal dialysis. Contrib Nephrol. Basel, Karger.
2006;150:214– 225.
9.- Cozzolinoa M, Stucchia A, Rizzoa MA, et al. Phosphate Control in
Peritoneal Dialysis. Contrib Nephrol. Basel, Karger. 2012;178:116–123.
10.- Pereira L, Mendonc L, Magalhães J, et al. Vascular calcification in
peritoneal dialysis patients and its association with bone-derived
molecules and bone Histomorphometry. Nefrologia. 2024;44(2):224–232.
11.- Barreto F, Costa C, Reis L et al. Bone biopsy in nephrology
practice. J Bras Nefrol
. 2018;40(4):366-374.
12.-Fusaro M, Re Sartò GV, Gallieni M et al. Time for Revival of Bone
Biopsy with Histomorphometric Analysis in Chronic Kidney Disease
(CKD):Moving from Skepticism to Pragmatism. Nutrients. 2022;14:1742.
13.- Ronco C, Rosner MH, Crepaldi. Phosphate Control in Peritoneal
Dialysis. Contrib Nephrol. Basel, Karger. 2012;178:116–123.
14.- Botelho C, Rodrigues A, Santos O. Phosphate removal in peritoneal
dialysis regimens: an underestimated adequacy parameter. NDT Plus.
2010;33(suppl 3):477– 478.
15.- Schmitt CP, Schaefer F, Huber D, et al: 1,25(OH)2- vitamin D3
reduces spontaneous and hypocalcemia- stimulated pulsatile component of
parathyroid hormone secretion. J Am Soc Nephrol. 1998;9:54–62.
16.-Nagy E, Sobh M, Abdalbary M et al. Is Adynamic Bone Always a
Disease? Lessons from Patients with Chronic Kidney Disease. J. Clin.
Med. 2022;11:7130.
17.- Sprague, S.M.; Bellorin-Font, E.; Jorgetti, V. et al. Diagnostic
accuracy of bone turnover markers and bone histology in patients with
CKD treated by dialysis. Am. J. Kidney Dis. 2016; 67:559–566.
18.-Wang AY. Calcium balance and negative impact of calcium load in
peritoneal dialysis patients. Perit Dial Int. 2014;34(4):345-52.
19.- Gotch FA, Kotanko P, Thijssen S, et al. The KDIGO guideline for
dialysate calcium will result in an increased incidence of calcium
accumulation in hemodialysis patients. Kidney Int. 2010; 78:343–50.
20.- Hill KM, Martin BR, Wastney ME et al. Oral calcium carbonate
affects calcium but not phosphorus balance in stage 3–4 chronic kidney
disease. Kidney Int. 2013; 83:959–66.
21.-Spasovski G, Gelev S, Masin-Spasovska J et al. Improvement of bone
and mineral parameters related to adynamic bone disease by diminishing
dialysate calcium. Bone. 2007; 40:698–703.
22.-Sethi S, Dhooria HS, Goyal S. Study on the Effect of Low Calcium
Dialysate on Biochemical Profile of Adynamic Bone Disease in Patients on
Maintenance Hemodialysis. Saudi J Kidney Dis Transpl.
2023;34(3):224-234.
23.-Mathew S, Lund R, Strebeck F et al. Reversal of the Adynamic Bone
Disorder and Decreased Vascular Calcification in Chronic Kidney Disease
by Sevelamer Carbonate Therapy. Journal of the American Society of
Nephrology. 2007;18(1):122-130.
24.- Ferreira A, Fraza˜o JM, Monier-Faugere MC et al. Effects of
sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in
hemodialysis patients. J Am Soc Nephrol 2008; 19: 405–412.
25.-Frazao J and Adragao T. Treatment of hyperphosphatemia with
sevelamer hydrochloride in dialysis patients: effects on vascular
calcification, bone and a close look into the survival data. Kidney
International.2008;74: S38–S43.
26.- Nigwekar SU, Brunelli SM, Meade D, et al: Sodium thiosulfate
therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol.2013;
8: 1162–1170.
27.-O’Neill WC, Hardcastle KI. The chemistry of thiosulfate and vascular
calcification. Nephrol Dial Transplant.2012;27:5216.
28.-Malbos S, Urena-Torres P, Cohen-Solal M et al. Sodium thiosulphate
treatment of uraemic tumoral calcinosis. Rheumatology.2014;53:547-551.
29.- Yatzidis H, Agroyannis B. Sodium thiosulfate treatment of
soft-tissue calcifications in patients with end-stage renal disease.
Perit Dial Bull. 1987;7:2502.
30.- Kyriakopoulos G, Kontogianni K. Sodium thiosulfate treatment of
tumoral calcinosis in patients with end-stage renal disease. Ren
Fail.1990;12:2139.
31.- Papadakis JT, Patrikarea A, Digenis GE et al. Sodium thiosulfate in
the treatment of tumoral calcifications in a hemodialysis patient
without hyperparathyroidism. Nephron 1996;72:30812.